OncoMatch/Clinical Trials/NCT06008054
A Study of SI-B003, BL-B01D1+SI-B003 and BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Esophageal Cancer, Gastric Cancer, Colorectal Cancer and Other Gastrointestinal Tumors
Is NCT06008054 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including SI-B003 and BL-B01D1 for esophageal cancer.
Treatment: SI-B003 · BL-B01D1 · PD-1 Monoclonal Antibody — This phase II study is a clinical study to explore the efficacy and safety of SI-B003 Monotherapy, BL-B01D1+SI-B003 Combination Therapy and BL-B01D1+PD-1 Monoclonal Antibody in patients with locally advanced or metastatic esophageal cancer, gastric cancer, colorectal cancer and other gastrointestinal tumors.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Esophageal Carcinoma
Gastric Cancer
Colorectal Cancer
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Cannot have received: antitumor therapy (chemotherapy or biological therapy)
Antitumor therapy such as chemotherapy or biological therapy was used within 4 weeks or 5 half-lives before the first dose in this study
Cannot have received: mitomycin (mitomycin)
Mitomycin and nitrosoureas were administered within 6 weeks before the first dose
Cannot have received: nitrosoureas (nitrosoureas)
Mitomycin and nitrosoureas were administered within 6 weeks before the first dose
Cannot have received: oral fluorouracil (fluorouracil)
Oral drugs such as fluorouracil
Cannot have received: antibody-drug conjugate
Exception: Cohort using BL-B01D1, previously treated with an ADC drug with topoisomerase I inhibitor as toxin
Cohort using BL-B01D1, previously treated with an ADC drug with topoisomerase I inhibitor as toxin
Cannot have received: immunomodulatory drugs
Immunomodulatory drugs were administered within 2 weeks before the first dose in this study
Lab requirements
Cardiac function
no severe cardiac dysfunction, left ventricular ejection fraction ≥50%
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06008054 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior antitumor therapy (chemotherapy or biological therapy), mitomycin, nitrosoureas disqualifies patients from enrollment.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages